Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles
By Amit Chowdhry ● Mar 18, 2025
Curevo Vaccine - a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability - announcd the closing of a $110 million Series B round to advance the development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi (a European biotech-focused investment firm). And joining Medicxi is an international group of investment funds, including OrbiMed, HBM Healthcare Investments, and Sanofi Ventures along with existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma.